TOPOGRAPH (Therapy-Oriented Precision Oncology Guidelines for Recommending Anti-cancer PHarmaceuticals) is an independent, oncologist-led effort of cataloguing literature and evidence to streamline the process of recommending drug treatments in precision cancer medicine.
This resource is intended to help oncologists find relevant literature when making treatment decisions for patients with advanced or metastatic cancer, using contemporary genomic profiling results and other assays.
TOPOGRAPH is a knowledgebase of predictive biomarkers in oncology and haematology, linking their therapeutic effects of anticancer drugs on the basis of published evidence. The types of biomarkers linked to therapies include but are not limited to:
Currently, TOPOGRAPH provides contents with reference to the Australian public health system. This resource is actively maintained as part of a nation-wide precision oncology program.
TOPOGRAPH is available under a dual licensing model designed to encourage both academic research and commercial innovation while protecting the integrity of the database and ensuring improvements benefit the precision oncology community.
TOPOGRAPH adopts a ShareAlike approach for database modifications to foster collaborative knowledge sharing in precision oncology. This ensures that improvements to the core database benefit the entire precision oncology community.
By requiring that database modifications remain open, we create a sustainable ecosystem where commercial innovation thrives while core knowledge remains accessible to researchers, clinicians, and patients worldwide. This approach has proven successful in other scientific domains and aligns with best practices in precision medicine data sharing.
Yes. Commercial products that use TOPOGRAPH data are explicitly encouraged. You can build clinical decision support software, integrate TOPOGRAPH into proprietary healthcare platforms, create subscription services, or develop mobile applications using this data.
We believe this approach encourages innovation in precision oncology tools while ensuring improvements to the core database benefit everyone.
We welcome contributions! If you've identified errors, have additional literature evidence, or want to suggest new therapeutic associations, please contact Frank Lin to discuss your contributions.
TOPOGRAPH does not accept responsibility for the accuracy or completeness of the curation content.